[Business Wire] – Bristol-Myers Squibb Company today presented 24-week Phase IIb data that demonstrated similar response rates for its investigational compound, BMS-663068, when compared to a boosted protease inhibitor, Reyataz® with ritonavir.
Read more on this.
Bristol-Myers Squibb Company (BMY), valued at $93.91B, started the session at $56.22.
Looking at the equity, the company’s one day range is $55.52 to $57.06 with a trailing 52-week range being $37.26 to $57.06.
BMY shares are currently priced at 30.05x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s 12.08x earnings multiple.
The company pays shareholders $1.44 per share annually in dividends, yielding 2.70%.
In a review of the consensus earnings estimate this quarter, 13 sell-side analysts are looking at $0.45 per share, which would be $0.04 better than the year-ago quarter and a $0.00 sequential decrease. Furthermore, our analysis shows the full-year EPS estimate to be $1.78, which would be a $0.04 setback when compared to the last year’s annual results.
The quarterly earnings estimate is predicated on a consensus revenue forecast of $4.03 Billion. If reported, that would be a 5.22% increase over the year-ago quarter.
More recently, Barclays upgraded BMY from Equal Weight to Overweight (Jan 10, 2014). Previously, Jefferies downgraded BMY from Buy to Hold.
Investors should keep in mind is that the average price target is $55.06, which is 2.06% below where the stock opened this morning.
Bristol-Myers Squibb Company (NYSE:BMY), a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes and sells biopharmaceutical products that help patients prevail over serious diseases worldwide.
Tag Helper ~ Stock Code: BMY | Common Company name: Bristol-Myers Squibb | Full Company name: Bristol-Myers Squibb Company (NYSE:BMY) .